Table 1.
Basic characteristics of all included studies
| Author | Year | Country | Molecular stratification | Included period | Sample size | Age, years Median (range) |
Clinical stage | Ethnicity | Treatment | Survival outcomes | Cut-off value (10^9) | Cut-off determination | Follow-up, months Median (range) |
NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| De Giorgi | 2019 | Italy | Mixed | 2004–2009 | 516 | 59 | IV | Caucasian | No‐surgery | OS | 836 | ROC analysis | 24 | 8 |
| Li | 2019 | China | Luminal BC | 2008–2013 | 161 | 58 | I–III | Asian | No-surgery | DFS | 518 | ROC analysis | 28.4 (1–79) | 7 |
| Liu | 2019 | China | TNBC | 2000–2012 | 160 | NA | I–III | Asian | Mixed | OS, DFS, DMFS | 557 | ROC analysis | 61.7 (5.9–159.0) | 6 |
| Sun | 2019 | China | HER2+ | 2002–2012 | 155 | NA | I–III | Asian | Mixed | OS, DFS, DMFS | 578 | Median value | 57.6 (10.4–158.2) | 6 |
| Wang | 2019 | China | TNBC | 2008–2016 | 215 | NA | I–III | Asian | Mixed | OS, DFS | 624 | Median value | 49.2 (4–105) | 7 |
| Chen | 2020 | China | Mixed | 1999–2014 | 262 | 48 (27–73) | II–III | Asian | No-surgery | OS, DFS | 602 | ROC analysis | NA | 8 |
| Hua | 2020 | China | Mixed | 2010–2012 | 1026 | 47 (22–87) | I–III | Asian | Mixed | OS, RFS, DMFS | 601.7 | ROC analysis | 68.5 (0.9–87.5) | 7 |
| Jiang | 2020 | China | HER2+ | 2011–2015 | 147 | NA | I–III | Asian | Mixed | OS, DFS | 442 | ROC analysis | 42 (15–78) | 7 |
BC breast cancer, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor-2, OS overall survival, DFS disease-free survival, RFS recurrence-free survival, DMFS distant metastasis-free survival, ROC receiver operating characteristics, NA not available, NOS Newcastle–Ottawa Scale